Boston Scientific (BSX) Stock Price & Analysis

BSX$44.20-0.93 -2.06%
Medical - DevicesLarge CapValue StockGrowth StockHigh Quality
Compare
Market cap$64.07BEnterprise value$77.75BRevenue (TTM)$21.07BMarket positionTop 25%

Score

65
Bullish
Value
73
Quality
61
Growth
60

AI Analysis

Snapshot

Boston Scientific is primarily a valuation case — Value 73/100 at P/E 19.3, about 68% below its own multi-year median — with the overall score at 65/100. Under the hood: P/E 19.3, about 68% below its own multi-year median, plus revenue compounding ~17% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

73
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

60
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

61
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Boston Scientific Corporation (BSX) last printed $44.20. Equity value is $64.07B. Trailing earnings multiple 18.42. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$8.39B$9.05B$9.82B$10.73B$9.91B$11.89B$12.68B$14.24B$16.75B$20.07B

About

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Boston Scientific (BSX) Stock Price & Analysis

BSX price $44.20 -0.93 -2.06%

Ticker
BSX
Price
$44.20
Change
-0.93 -2.06%
Market cap
$64.07B
P/E
18.42
Forward P/E
14.36
Dividend yield
0.00%
Beta
0.58
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
65
Value
73
Quality
61
Growth
60

Stocklytics score rationale: value 73, quality 61, growth 60.

AI Score 75. Boston Scientific Corporation (BSX) has a solid market capitalization of approximately $64.2 billion and a price of $44.32, with a price-to-earnings ratio of about 18.7, indicating reasonable valuation. The company shows strong profitability with a net profit margin of 16.6% and a robust operating cash flow ratio of 0.707, suggesting good operational efficiency and growth potential in the healthcare sector

Fair value

BSX fair value $86.71. Price $44.20. Price is 49% below fair value.

Below fair value, and cheaper than usual. A larger discount than on more than 99% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 30.0, a blend of the Medical - Devices median (28.6) and the stock's own 10-year median (57.4). How we calculate it →

Compare BSX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-03—0.78—5.19B
2026-10-280.730.735.14B5.09B
2026-07-290.860.835.44B5.38B
2026-04-220.800.795.20B5.17B
2026-02-040.800.785.29B5.28B
2025-10-220.750.715.07B4.97B
2025-07-230.750.725.06B4.89B
2025-04-230.750.674.66B4.57B
2025-02-050.700.664.56B4.42B
2024-10-230.630.594.21B4.04B
2024-07-240.620.584.12B4.03B
2024-04-240.560.513.86B3.68B
2024-01-310.550.513.73B3.59B
2023-10-260.500.483.53B3.47B
2023-07-270.530.493.60B3.50B
2023-04-260.470.433.39B3.16B
2023-02-010.450.473.24B3.24B
2022-10-260.430.443.17B3.14B
2022-07-270.440.423.24B3.22B
2022-04-270.390.383.03B2.96B
2022-02-020.450.443.13B3.11B
2021-10-270.410.402.93B3.00B
2021-07-270.400.373.08B3.02B
2021-04-280.370.302.75B2.62B
2021-02-030.230.312.71B2.81B
2020-10-280.370.252.66B2.28B
2020-07-290.080.022.00B500.75M
2020-04-290.280.332.54B2.82B
2020-02-050.460.442.90B2.78B
2019-10-230.390.382.71B2.64B
2019-07-240.390.382.63B2.56B
2019-04-240.350.362.49B2.56B
2019-02-060.390.372.56B2.43B
2018-10-240.350.342.39B2.32B
2018-07-250.410.342.49B2.42B
2018-04-250.330.312.38B2.31B
2018-02-010.340.342.41B2.41B
2017-10-260.310.312.22B2.22B
2017-07-270.320.312.26B2.19B
2017-04-270.290.302.16B2.23B

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-11-04Mahoney Michael FBuy102.25K——
2026-11-04Mahoney Michael FBuy149.99K——
2026-11-01O'Sullivan MiriamBuy3.87K——
2026-11-01O'Sullivan MiriamSell1.87K$41.9878.59K
2026-11-01O'Sullivan MiriamSell3.87K——
2026-09-02O'Connor Padraig AndrewBuy1.17K——
2026-09-02O'Connor Padraig AndrewSell567$48.3727.43K
2026-09-02O'Connor Padraig AndrewSell1.17K——
2026-08-25Morano Susan EBuy2.04K$49.22100.41K
2026-08-11Woodworth EmilyBuy2.93K$51.19149.99K
2026-08-10Monson JonathanBuy9.91K$50.46499.96K
2026-08-05Habiger David CBuy2.10K$47.5999.94K
2026-08-04Habiger David CBuy140$48.596.80K
2026-08-03Habiger David CBuy1.04K$48.0750.08K
2026-08-03Mahoney Michael FBuy186.24K$48.339.00M
2026-08-03Mahoney Michael FBuy22.12K$48.431.07M
2026-07-31LUDWIG EDWARD JBuy5.00K$45.48227.40K
2026-07-31Fitzgerald Joseph MichaelBuy64.20K$46.733.00M
2026-07-01Monson JonathanBuy2.09K——
2026-07-01Monson JonathanSell1.01K$43.0643.49K
2026-07-01Monson JonathanSell2.09K——
2026-05-28Mahoney Michael FSell386.75K——
2026-05-20Pegus CherylBuy1.77K$56.4999.99K
2026-05-20LUDWIG EDWARD JBuy3.58K$56.68202.91K
2026-05-20Habiger David CBuy2.25K$55.92125.82K
2026-05-19Habiger David CBuy2.20K$56.95125.28K
2026-05-07Zane Ellen MBuy3.80K——
2026-05-07WICHMANN DAVID SBuy3.80K——
2026-05-07Weber Christophe PierreBuy1.14K——
2026-05-07Weber Christophe PierreBuy2.66K——
2026-05-07Weber Christophe PierreBuy1.77K——
2026-05-07Smith Cathy RBuy2.21K——
2026-05-07Smith Cathy RBuy3.80K——
2026-05-07Pegus CherylBuy1.28K——
2026-05-07Pegus CherylBuy3.80K——
2026-05-07Morano Susan EBuy1.28K——
2026-05-07Morano Susan EBuy3.80K——
2026-05-07Mega Jessica LBuy3.80K——
2026-05-07LUDWIG EDWARD JBuy3.80K——
2026-05-07Habiger David CBuy3.80K——
2026-05-02O'Connor Padraig AndrewBuy1.80K——
2026-05-02O'Connor Padraig AndrewSell872$56.5049.27K
2026-05-02O'Connor Padraig AndrewSell1.80K——
2026-05-02Butcher Arthur CBuy2.10K——
2026-05-02Butcher Arthur CSell1.01K$56.5056.90K
2026-05-02Butcher Arthur CSell2.10K——
2026-03-02Pegus CherylBuy24——
2026-03-02Morano Susan EBuy24——
2026-03-02Weber Christophe PierreBuy323——
2026-03-02Weber Christophe PierreBuy556——
2026-03-02Smith Cathy RBuy323——
2026-03-02Smith Cathy RBuy556——
2026-03-01Woodworth EmilyBuy838——
2026-03-01Woodworth EmilySell372$76.8528.59K
2026-03-01Woodworth EmilySell838——
2026-02-19Butcher Arthur CBuy6.85K$75.76519.03K
2026-02-18Weber Christophe PierreOther0——
2026-02-18Smith Cathy ROther0——
2026-02-16O'Connor Padraig AndrewBuy905——
2026-02-16O'Connor Padraig AndrewSell339$74.7325.33K
2026-02-16O'Connor Padraig AndrewSell905——
2026-02-16Woodworth EmilyBuy637——
2026-02-16Woodworth EmilySell283$74.7321.15K
2026-02-16Woodworth EmilySell637——
2026-02-16Monson JonathanBuy990——
2026-02-16Monson JonathanSell440$74.7332.88K
2026-02-16Monson JonathanSell990——
2026-02-16O'Sullivan MiriamBuy990——
2026-02-16O'Sullivan MiriamSell291$74.7321.75K
2026-02-16O'Sullivan MiriamSell990——
2026-02-16Mahoney Michael FBuy16.27K——
2026-02-16Mahoney Michael FSell7.87K$74.73587.75K
2026-02-14O'Connor Padraig AndrewBuy1.19K——
2026-02-14O'Connor Padraig AndrewSell449$74.7333.55K
2026-02-14O'Connor Padraig AndrewSell1.19K——
2026-02-14Woodworth EmilyBuy661——
2026-02-14Woodworth EmilySell296$74.7322.12K
2026-02-14Woodworth EmilySell661——
2026-02-14Monson JonathanBuy1.06K——
2026-02-14Monson JonathanSell470$74.7335.12K
2026-02-14Monson JonathanSell1.06K——
2026-02-14O'Sullivan MiriamBuy1.12K——
2026-02-14O'Sullivan MiriamSell329$74.7324.59K
2026-02-14O'Sullivan MiriamSell1.12K——
2026-02-14Mahoney Michael FBuy16.52K——
2026-02-14Mahoney Michael FSell7.99K$74.73597.09K
2026-02-13O'Connor Padraig AndrewBuy500——
2026-02-13O'Connor Padraig AndrewSell199$74.7314.87K
2026-02-13O'Connor Padraig AndrewSell500——
2026-02-13Woodworth EmilySell1.41K——
2026-02-13Woodworth EmilyBuy1.41K——
2026-02-13Woodworth EmilySell690$74.7351.56K
2026-02-13Monson JonathanBuy1.77K——
2026-02-13Monson JonathanSell788$74.7358.89K
2026-02-13Monson JonathanSell1.77K——
2026-02-13O'Sullivan MiriamBuy588——
2026-02-13O'Sullivan MiriamSell200$74.7314.95K
2026-02-13O'Sullivan MiriamSell588——
2026-02-13Mahoney Michael FBuy8.83K——
2026-02-13Mahoney Michael FBuy132.19K——

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 1.32K, holders -258 vs prior quarter. Ownership 69.64%.

HolderSharesChangeChange %Value
BLACKROCK, INC.125.56M-4.12M-3.18%5.48B
VANGUARD CAPITAL MANAGEMENT LLC94.91M-2.18M-2.24%4.14B
STATE STREET CORP67.32M-2.79M-3.98%2.94B
PRIMECAP MANAGEMENT CO/CA/58.62M8.10M+16.04%2.56B
MASSACHUSETTS FINANCIAL SERVICES CO /MA/43.05M18.20M+73.19%2.29B
VANGUARD PORTFOLIO MANAGEMENT LLC45.39M15.60M+52.35%1.98B
FMR LLC40.12M-5.59M-12.23%1.75B
GEODE CAPITAL MANAGEMENT, LLC34.47M1.03M+3.07%1.50B
CAPITAL WORLD INVESTORS29.32M12.51M+74.41%1.28B
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP28.47M5.17M+22.20%1.24B
FRANKLIN TEMPLETON INC26.47M12.70M+92.19%1.21B
JPMORGAN CHASE & CO19.17M-4.74M-19.83%841.00M
BOLLARD GROUP LLC18.42M00.00%804.06M
MORGAN STANLEY18.09M-854.81K-4.51%789.73M
JANE STREET GROUP, LLC17.27M11.68M+209.05%753.91M
CAPITAL RESEARCH GLOBAL INVESTORS17.24M3.06M+21.59%752.60M
INVESCO LTD.16.34M2.54M+18.40%713.27M
AMUNDI16.08M1.79M+12.50%702.03M
DODGE & COX14.96M14.96MNew653.05M
FIL LTD12.72M387.98K+3.15%555.23M
UBS GROUP AG11.29M-5.06M-30.96%492.80M
BARCLAYS PLC10.88M10.88MNew475.04M
JANE STREET GROUP, LLC9.30M3.71M+66.42%405.97M
VANGUARD FIDUCIARY TRUST CO8.19M-159.67K-1.91%357.31M
NUVEEN, LLC7.82M-871.82K-10.03%341.49M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener